Clinical trials: COVID-19 Vaccines
COVID-19
Safety and Immunogenicity of SCB-2019 in Children <18 Years of Age
This is a phase 2/3, randomized, controlled study to assess the reactogenicity, safety and immunogenicity of adjuvanted recombinant SARS-CoV-2 trimeric S-protein subunit vaccine (SCB-2019), when administered as 2-dose vaccination…
- Trial name
- NCT05193279
- Testing
- Candidate vaccine, SCB-2019
- Where
- 2 sites in Colombia
- Volunteers
- healthy volunteers welcome
- Sponsor
- Clover Biopharmaceuticals AUS Pty
Quality of Life, Injection Site Reaction
Simultaneous mRNA COVID-19 and IIV4 Vaccination Study
This study is a prospective, randomized clinical trial. During this study, participants will be randomly assigned to receive quadrivalent inactivated influenza vaccine (IIV4) and mRNA COVID-19 vaccine either simultaneously or…
- Conditions
- Quality of Life, Injection Site Reaction, Adverse Drug Event, Systemic Reaction
- Trial name
- NCT05028361
- Testing
- mRNA COVID-19, IIV4
- Where
- 3 sites in United States
- Volunteers
- 348 people, healthy volunteers welcome
- Sponsor
- Duke University
COVID-19, COVID-19 Serological Testing
COVID-19 Serologies Among Healthcare Workers at CHSD (SERO2)
This study looks at how many healthcare workers at CHSD hospital developed antibodies against COVID-19 after the second and third waves of the pandemic and after receiving a vaccine.
- Conditions
- COVID-19, COVID-19 Serological Testing, COVID-19 Vaccines, Health Personnel
- Trial name
- NCT06989307
- Where
- France
- Volunteers
- 447 people
- Sponsor
- Centre Hospitalier de Saint-Denis
SARS-CoV-2 Infection, COVID-19
A Study to Learn About New COVD-19 RNA Vaccine Candidates for New Variants in Healthy Individuals
The purpose of this clinical protocol is to learn about the safety, tolerability, and immunogenicity of new BNT162b2 RNA-based vaccine candidates targeting new variants of SARS-CoV-2 in healthy people.
- Trial name
- NCT05997290
- Testing
- BNT162b2 (Omi XBB.1.5), BNT162b2 (Omi JN.1), BNT162b2 (Omi KP.2)
- Where
- 37 sites in United States
- Volunteers
- 1,051 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
Corona Virus Infection, Flu Vaccine
Understanding Immunity to the Flu Vaccine in COVID-19 Patients
The purpose of this study is to measure immunity to the flu vaccine over time in patients who have had COVID-19 and may have other medical conditions including obesity, type 2 diabetes, chronic fatigue, or long-term COVID-19…
- Conditions
- Corona Virus Infection, Flu Vaccine, Immunity
- Trial name
- NCT04579588
- Testing
- Flu shot
- Where
- United States
- Volunteers
- 230 people, healthy volunteers welcome
- Sponsor
- Stanford University
Healthy
Convalescent Plasma Donor Vaccine Study An Observational Antibody Level Study.
There is a need to understand antibody responses following SARS-COV-2 infection and subsequent vaccination.
- Trial name
- C-VELVET (NCT04954937)
- Where
- United Kingdom
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- NHS Blood and Transplant
COVID-19
A Clinical Trial to Evaluate the Recombinant SARS-CoV-2 Vaccine (CHO Cell) for COVID-19
phase I study will evaluate safety and immunogenicity of a recombinant SARS-CoV-2 vaccine (CHO cell) in Chinese healthy population aged 3 years and older.
- Trial name
- NCT04869592
- Testing
- low-dose Recombinant SARS-CoV-2 Vaccine (CHO cell), high-dose Recombinant SARS-CoV-2 Vaccine (CHO cell)
- Where
- China
- Volunteers
- 3,100 people, healthy volunteers welcome
- Sponsor
- National Vaccine and Serum Institute, China
Vaccine
Double-blind, Placebo-controlled, Randomized Study of the Tolerability, Safety and Immunogenicity of an Inactivated Whole Virion Concentrated Purified Vaccine (CoviVac) Against Covid-19 of Children at the Age of 12-17 Years Inclusive"
Randomized, double-blind, placebo controlled, multi-center clinical trials of the tolerability, safety and immunogenicity of the inactivated whole-virion concentrated purified vaccine against COVID-19, manufactured by FSBSI…
- Trial name
- NCT05715918
- Testing
- Vaccine for intramuscular injection
- Where
- 4 sites in Russia
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products
SARS-CoV-2 Infection, COVID-19
A Phase 3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of Multiple Production Lots and Dose Levels of BNT162b2 RNA-Based COVID-19 Vaccines Against COVID-19 in Healthy Participants
This is a Phase 3, randomized, observer-blind study in healthy individuals. The primary study will evaluate the safety, tolerability, and immunogenicity of the SARS-CoV-2 RNA vaccine candidate (BNT162b2): As a 30-microgram dose…
- Trial name
- NCT04713553
- Testing
- BNT162b2, BNT162b2.B.1.351
- Where
- 17 sites in United States
- Volunteers
- 1,574 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
COVID-19, SARS-CoV-2 Infection
A Study to Evaluate the Immunogenicity and Safety of A Recombinant Protein COVID-19 Vaccine as Booster Vaccines
This study is a phase Ⅱ clinical trial to evaluate the safety and immunogenicity of SCTV01E-2 in people of different ages who had been vaccinated with COVID-19 vaccines.
- Trial name
- NCT05933512
- Testing
- SCTV01E-2, SCTV01E
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Sinocelltech Ltd.
X-linked Agammaglobulinemia, XLA
COVID-19 Vaccine Responses in PIDD Subjects
The goal of our study is to assess the cellular immune responses of participants with antibody deficiency disease before and after immunization with SARS-CoV-2 mRNA vaccines.
- Conditions
- X-linked Agammaglobulinemia, XLA, Primary Immune Deficiency, CVID
- Trial name
- NCT05321407
- Where
- 3 sites in United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Duke University
COVID-19 Vaccines
Improving COVID-19 Vaccine Uptake in Nursing Homes
SARS-CoV-2 vaccine, now being administered to skilled nursing facility (SNF) residents and staff, has highly variable acceptance between facilities.
- Trial name
- NCT04732819
- Testing
- High touch multi-pronged behavioral intervention
- Where
- 4 sites in United States
- Volunteers
- 23,768 people
- Sponsor
- Brown University
Vaccine Uptake
Boosting COVID-19 Vaccination Uptake Using Wastewater Surveillance
Vaccinations are among the most successful and critical public health interventions. Despite the enormous protection that vaccines provide to public health, both delays and refusals of vaccines (vaccine hesitancy) are on the…
- Trial name
- NCT06698497
- Testing
- Communication Campaign
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Syracuse University
Fertility Issues, Vaccine Adverse Reaction
COVID-19 Vaccine and Ovarian Reserve
As Israel is the first country to widely vaccinate its population using the mRNA vaccine against COVID-19, evaluating its influence on ovarian reserve is essential .
- Trial name
- NCT04748172
- Testing
- SARS-CoV-2 virus vaccines, AMH sampling, anti Covid-19 antibody levels (Serology)
- Where
- Israel
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Sheba Medical Center
COVID -19, SARS CoV 2 Infection
Evaluating Safety and Immune Response of Janssen, Moderna, Pfizer/BNT, and Novavax COVID-19 Vaccines for Same and Mixed Boosters in Adolescents and Adults Aged 12-64 With and Without HIV in Kenya, DRC, and Rwanda
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel coronavirus that emerged in the human population in Wuhan City, Hubei Province, China in December 2019.
- Trial name
- NCT07408297
- Testing
- Janssen Ad26COVS1, Pfizer-BioNTech vaccine COVID-19 vaccine, Inactivated Sinopharm or Sinovac COVID-19 vaccine
- Where
- Kenya
- Volunteers
- 1,919 people, healthy volunteers welcome
- Sponsor
- Victoria Biomedical Research Institute
COVID-19
Lot-to-lot Consistency of an Inactivated SARS-CoV-2 Vaccine Between Different Workshops in Healthy Children Aged 3-17 Years
This study is a double-blind, randomized phase Ⅳ clinical trial of the inactivated SARS-CoV-2 vaccine (CoronaVac)manufactured by Sinovac Research \& Development Co., Ltd.
- Trial name
- NCT05112913
- Testing
- Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 1 of the workshop 2, Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 2 of the workshop 2, Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 3 of the workshop 2
- Where
- China
- Volunteers
- 2,520 people, healthy volunteers welcome
- Sponsor
- Sinovac Research and Development Co., Ltd.
SARS-CoV-2
A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations
The purpose of this study is to investigate the immunogenicity and safety of mRNA COVID-19 variant-containing vaccine formulations against the vaccine-matched variants and newly emerged variants of severe acute respiratory…
- Trial name
- NCT06585241
- Testing
- mRNA-1273 Variant-containing Formulation
- Where
- 6 sites in United States
- Volunteers
- 1,144 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
COVID-19 Vaccine
SARS-CoV-2 Antibody Response in Children Aged 5-11 Years Following Vaccination Against COVID-19
There are few data on the immunogenicity of the Pfizer-Biontec BNT162b2 vaccine for the prevention of COVID-19 disease and of side effects in children aged 5-11 years.
- Trial name
- NCT05175989
- Where
- Israel
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Rabin Medical Center
Coronavirus Disease 2019, Vaccinia
Comparison of General Characteristics of Patients Diagnosed COVID-19 (Coronavirus )Positive Followed In Service
comparison of general characteristics of patients diagnosed COVID-19 positive followed In service
- Conditions
- Coronavirus Disease 2019, Vaccinia, Symptoms and Signs
- Trial name
- COVID-19 (NCT05092568)
- Where
- Turkey (Türkiye)
- Volunteers
- 45 people
- Sponsor
- Saglik Bilimleri Universitesi
IBD, Covid19
Covid-19 Vaccine Responses in Patients With Inflammatory Bowel Diseases
The 2019-coronavirus disease (COVID-19), caused by SARS-CoV-2, was identified as the source of pneumonia cases in Wuhan city in China. It rapidly spread worldwide and was declared by WHO as a pandemic.
- Trial name
- NCT05067959
- Testing
- Covid-19 vaccine
- Where
- Israel
- Volunteers
- 284 people, healthy volunteers welcome
- Sponsor
- Rabin Medical Center